TGFBR1 and Hepatic fibrosis: In vivo results showed that CCL4 treatment could increase the expression of TGF-β1, TβR-I, Smad 2, and Smad 3 in liver tissue and inhibit the expression of Smad 7, thereby reducing the formation of liver fibrosis.